CompletedPhase 3NCT01473524
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Intercept Pharmaceuticals
- Principal Investigator
- Christian Weyer, MDIntercept Pharmaceuticals, Inc.
- Intervention
- Obeticholic Acid (OCA)(drug)
- Enrollment
- 217 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2018
Study locations (30)
- UC Davis Medical Center, Sacramento, California, United States
- Scripps Clinic, San Diego, California, United States
- University of Colorado, Denver, Aurora, Colorado, United States
- University of Chicago, Chicago, Illinois, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- Henry Ford Health System, Detroit, Michigan, United States
- St. Louis University, St Louis, Missouri, United States
- Beth Israel Medical Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Baylor College of Medicine, Houston, Texas, United States
- Liver Institute of Virginia, Newport News, Virginia, United States
- Liver Institute of Virginia, Richmond, Virginia, United States
- Virginia Commonwealth University/McGuire DVAMC, Richmond, Virginia, United States
- Swedish Medical Center, Seattle, Washington, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01473524 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta